AbCellera Biologics vs Vivani Medical
Free cash flow was −$174 million at AbCellera Biologics and −$25 million at Vivani Medical.
Side by side
| AbCellera Biologics | Vivani Medical | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $75M | $0M |
| Revenue growth | 160.6% | — |
| Revenue growth a year, last 5 years | −20.3% | — |
| Gross margin | — | — |
| Operating margin | −289.0% | — |
| Net margin | −194.9% | — |
| Free cash flow | −$174M | −$25M |
| Free cash flow margin | −231.7% | — |
| Return on capital | — | — |
| Net debt to EBITDA | — | — |
| Dividends and buybacks | $0M | $0M |
| Change in diluted share count | 1.5% | 13.5% |
| Last close | $10.47 | $1.09 |
| P/E at the last close | — | — |
| Insider trades, last 12 months | bought $2.7 million, sold $0 | bought $16.7 million, sold $0 |
| Piotroski F-score | — | — |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
AbCellera BiologicsVivani Medical
Operating margin
Percent of revenue
AbCellera BiologicsVivani Medical
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
AbCellera BiologicsVivani Medical
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the AbCellera Biologics and Vivani Medical pages.